Osteoporosis remains a global health challenge driven by an imbalance where osteoclasts—cells responsible for breaking down bone—outpace the bone-forming osteoblasts. While current treatments mitigate bone loss, they often carry long-term side effects, necessitating the search for more precise molecular targets. A study led by Professor Jeong-Tae Koh, published in Cell Death & Differentiation, reveals that caspase-11 acts as a critical regulator in this process.

The research team observed elevated levels of caspase-11 in mouse models suffering from aging, periodontitis, and ovariectomy-induced osteoporosis. By utilizing genetic knockout techniques and the pharmacological inhibitor VX-765, the scientists demonstrated that caspase-11 is essential for RANKL-induced osteoclastogenesis. The protein functions by translocating to the cell nucleus, where it inactivates PARP1, a known suppressor of osteoclast development. Inhibiting this pathway effectively curbed bone resorption while preserving bone mass in vivo.

"We discovered that this protein unexpectedly controls bone-destroying cells, revealing a previously unknown role for an inflammation-associated protein in bone loss," Professor Koh stated. By moving beyond its established inflammatory functions, caspase-11 emerges as a promising target for future clinical interventions aimed at preventing skeletal degradation.